Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceArlene B. Chapman, David C. Wheeler, Terry Watnick et al.|Kidney International|2015Cited by 602
Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, Derralynn Hughes et al.|New England Journal of Medicine|2016Cited by 555
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancyOliver Groß, Manfred Weber, Christoph Licht et al.|Kidney International|2011Cited by 361
Expert consensus guidelines for the genetic diagnosis of Alport syndromeJudy Savige, Helen Storey, Francesca Ariani et al.|Pediatric Nephrology|2018Cited by 152
X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype CorrelationsMato Nagel, Helen Storey, Hae Il Cheong et al.|PLoS ONE|2016Cited by 102